Systemic Therapy for Advanced Hepatocellular Carcinoma

Last updated May 27, 2022

Key Points

Key Points

  • HCC is the fourth leading cause of cancer deaths worldwide, accounting for approximately 670,000 new cases and 625,000 deaths in 2018.
  • Atezolizumab + bevacizumab (atezo + bev) may be offered as first-line treatment for most patients with advanced HCC, following management of esophageal varices, when present.
  • Second-line therapy with a tyrosine kinase inhibitor may be recommended for appropriate candidates.

Treatment

...Treatment

...First-Line Thera...

...ion 1.1: Atezolizumab-bevacizumab (atezo + bev) m...

...commendation 1.2: Where there are contraindi...


...Second-L...

...dation 2.1: Following first-line treatment with...

....2. Following first-line therapy with sorafenib...

...commendation 2.3: Following first-line therapy...